Glimepiride tablets are the AB-rated generic equivalent of Aventis' antidiabetic agent Amaryl tablets.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) announced today that the US Food and Drug Administration has granted final approval for the company's ANDA for Glimepiride tablets, 1 mg, 2 mg and 4 mg.
Shipment of this product will begin immediately.
Teva's Glimepiride tablets are the AB-rated generic equivalent of Aventis' antidiabetic agent Amaryl tablets.
Teva stated that the brand product has US annual sales of approximately $350 million.
Published by Globes [online], Israel business news - www.globes.co.il - on Thursday, October 06, 2005